Recursion Pharmaceuticals Inc
General ticker "RXRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B
Recursion Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -16.5%.
Estimated limits based on current volatility of 6.4%: low 5.85$, high 6.65$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [6.41$, 13.94$]
- 2024-12-30 to 2025-12-30 estimated range: [6.32$, 13.80$]
Financial Metrics affecting the RXRX estimates:
- Negative: Non-GAAP EPS, $ of -1.55 <= 0.10
- Negative: Operating profit margin, % of -88.70 <= 1.03
- Negative: Operating cash flow per share per price, % of -14.29 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: -0.39 < Industry inventory ratio change (median), % of 0
Short-term RXRX quotes
Long-term RXRX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $10.18MM | $39.84MM | $44.58MM |
| Operating Expenses | $192.95MM | $285.57MM | $394.63MM |
| Operating Income | $-182.78MM | $-245.73MM | $-350.06MM |
| Non-Operating Income | $-3.70MM | $6.25MM | $17.93MM |
| Interest Expense | $2.95MM | $0.06MM | $0.10MM |
| R&D Expense | $135.27MM | $155.70MM | $241.23MM |
| Income(Loss) | $-186.48MM | $-239.48MM | $-332.13MM |
| Taxes | $0.00MM | $0.00MM | $-4.06MM |
| Profit(Loss) | $-186.48MM | $-239.48MM | $-328.07MM |
| Stockholders Equity | $542.94MM | $485.81MM | $463.44MM |
| Inventory | $1.55MM | $1.28MM | $0.00MM |
| Assets | $610.35MM | $701.29MM | $653.70MM |
| Operating Cash Flow | $-158.61MM | $-83.52MM | $-287.78MM |
| Capital expenditure | $39.80MM | $37.36MM | $11.96MM |
| Investing Cash Flow | $-271.74MM | $193.25MM | $-10.23MM |
| Financing Cash Flow | $458.54MM | $154.34MM | $140.13MM |
| Earnings Per Share* | $-1.05 | $-1.36 | $-1.58 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.